254750-02-2

Basic information

• Product Name: (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
• Synonyms: (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid;IDN 6556;(3S)-3-[(N-{[(2-tert-butylphenyl)amino](oxo)acetyl}-L-alanyl)amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid;(S)-3-((S)-2-(2-(2-tert-butylphenylaMino)-2-oxoacetaMido)propana;EMricasan;N-[2-(tert-butyl)phenyl]-2-oxoglycyl-N-[(1S)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]-L-alaninamide;PF 03491390;(S)-3-((S)-2-(2-((2-(tert-Butyl)phenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetraf
• CAS NO: 254750-02-2
• Molecular Formula: C26H27F4NO7
• Molecular Weight: 569.5020928
• Mol File: 254750-02-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.386
• Refractive Index: 1.55
• Storage Temp.: -20°C
• PKA: 3.91±0.19(Predicted)
• CAS DataBase Reference: (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid(254750-02-2)
• EPA Substance Registry System: (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid(254750-02-2)

Safety Data

• Hazardous Substances Data: 254750-02-2(Hazardous Substances Data)

Usage

Description

(S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid, also known as Emricasan, is a pharmaceutical compound with a complex chemical structure. It is an irreversible pan-caspase inhibitor that targets the caspase family of protease enzymes, which play a crucial role in the regulation of apoptosis and inflammation.

Uses

Used in Pharmaceutical Industry:
Emricasan is used as a therapeutic agent for the treatment of various conditions associated with caspase-mediated apoptosis and inflammation. It has shown potential in reducing hepatic injury and liver fibrosis, making it a promising candidate for the treatment of liver diseases.
Used in Anti-apoptotic Applications:
As an irreversible pan-caspase inhibitor, Emricasan is used to prevent caspase-mediated apoptosis, which is a form of programmed cell death. This property makes it useful in the treatment of conditions where excessive apoptosis contributes to tissue damage or disease progression.
Used in Anti-inflammatory Applications:
Emricasan also has anti-inflammatory effects by inhibiting caspase-mediated inflammation pathways. This makes it a potential treatment option for inflammatory disorders where caspase activation contributes to the disease process.

InChI:InChI=1/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1

Upstream product

• 68259-67-6 N-Pyruvoyl-L-alanin-methylester 
• 2392-63-4 N-Pyruvyl-L-alanin 
• 409369-36-4 (3S)-3-[N-(N'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid benzyl ester 
• 254751-08-1 2-((2-(tert-butyl)phenyl)amino)-2-oxoacetic acid 
• 483334-60-7 methyl 2-[N-(2-tert-butylphenylamino)]-2-oxoacetate 
• 3408-50-2 [(N-benzyloxycarbonyl)-L-alaninyl]-L-aspartic acid [beta]-tert-butyl ester 
• 6310-21-0 2-(1,1-dimethylethyl)-benzenamine 
• 254750-82-8 (3S)-3-[N-(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 
• 868565-57-5 (3S)-3-[(N-benzyloxycarbonyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid tert-butyl ester 
• 868565-58-6 (3S)-3-[(N-benzyloxycarbonyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 
• 254750-81-7 (3S)-3-(alaninyl)amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 
• 868565-55-3 (3S)-3-[(N-benzyloxycarbonyl)-L-alaninyl]amino-5-bromo-4-oxopentanoic acid tert-butyl ester 
• 254750-83-9 (3S)-3-[N-(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid tert-butyl ester 

Relevant articles and documents

A the graciousness favorable card lives synthetic method

A synthetic method for emricasan belongs to the technical field of drug chemical synthesis. The synthetic method comprises the steps: firstly carrying out acyl chlorination reaction on pyruvic acid and an acyl chlorination reagent to obtain pyruvoyl chlor

TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE

Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions

First-in-class pan caspase inhibitor developed for the treatment of liver disease

A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of α-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.